Growing demand for efficient, multi-ailment treatments has led to an increase in protein therapeutics. As chronic illnesses like diabetes, autoimmune disorders, and cancer increase, there is a growing need for protein-based therapies. The prevalence of these diseases has increased due to the rising global ageing population. Small-molecule drugs are not as well-liked as biologics. Due to biologics’ superior efficacy, less side effects, and great specificity, they are growing in popularity.
Protein Therapeutics Market size was valued at USD 242.58 billion in 2023 and is poised to grow from USD 257.13 billion in 2024 to USD 409.83 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).
The market has expanded due to the most common protein therapy, monoclonal antibodies. Protein engineering and biotechnology developments have propelled market expansion. Researchers and pharmaceutical companies have undertaken the use of advanced technologies to develop more potent protein medicines. Thus, augmenting therapeutic options to invent next-generation biologics like fusion proteins and bispecific antibodies.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/protein-therapeutics-market
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Protein Therapeutics Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Based on Type, the market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Human Growth Hormone, Erythropoietin and Interferon.
Based on Application, the market is segmented into Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others.
Based on End User, the market is segmented into Pharmaceutical companies, Healthcare Service Providers, Research Organizations and Academic Research Institutes.
Based on Function, the market is segmented into Vaccines, Enzymatic and Regulatory and Protein Diagnostics.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Protein Therapeutics Market – Regional Analysis:
North America dominates the global protein therapeutics market due to its advanced healthcare infrastructure, robust biotechnology sector, and significant investment in research and development. Innovation-based protein therapy development and approval, commercialization mostly occurs in the U.S.
This is complemented by the strong regulatory frameworks and an outsize presence of most pharmaceutical companies in the country. Chronic diseases like cancer and metabolic disorders are on the rise. Healthcare spending continues growing, and there is an increase in personalized medicine, which propels demand for protein therapeutics.
Asia-Pacific is the fastest-growing region in the global protein therapeutics market due to its rapidly expanding healthcare infrastructure, large patient population, and rising demand for advanced medical treatments. China and India are among those countries well-endowed with enormous economic growth and thus high healthcare investments and facilities for improved access to novel therapies.
Top Market Players in Protein Therapeutics Market are:
Johnson & Johnson (United States)
Roche (Switzerland)
Merck & Co. (United States)
Pfizer (United States)
AbbVie (United States)
Sanofi (France)
AstraZeneca (United Kingdom)
Novartis (Switzerland)
Bristol-Myers Squibb (United States)
Abbott Laboratories (United States)
GlaxoSmithKline (United Kingdom)
Novo Nordisk (Denmark)
Eli Lilly and Company (United States)
Amgen (United States)
Gilead Sciences (United States)
Biogen (United States)
Bayer (Germany)
Takeda Pharmaceutical Company (Japan)
CSL Behring (Australia)
Teva Pharmaceutical Industries (Israel)
Recent Developments:
In October 2023, Lumakras is the latest protein-based drug approved by the U.S. FDA for treating non-small cell lung cancer. The path-breaking monoclonal antibody is therefore well positioned in terms of targeted therapy for cancer. Thus, this demonstrates Amgen’s commitment to continuing to expand its oncology pipeline.
In July 2023, Roche launched this novel protein therapy with Hemlibra, specifically for hemophilia A patients. The therapy acts as a substitute for the deficient clotting factor and will yield better results as compared to the older treatment options available. This approval reaffirms Roche’s leadership in the field of innovating hematology.
In June 2023, A new invention from Johnson & Johnson is a protein-based vaccine for the Respiratory Syncytial Virus (RSV). This protein therapeutics approach is geared to help with fewer hospitalizations and severe symptoms among the most vulnerable populations. The vaccine is just the latest example of the continued effort expected from Johnson & Johnson in innovating targeted biologics for emerging infectious diseases.
You may Also Like
https://medium.com/@kathan.trivedi/liquid-biopsy-market-trends-growth-opportunities-and-future-outlook-41dda63f1397
https://medium.com/@kathan.trivedi/crypto-currency-market-trends-opportunities-and-segmentation-becad901b694
Forward-Looking Insights
The Protein Therapeutics Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
